Try searching for...
A/Prof John Park
MBBS BSc (Med) MPH FRACP PhD
For patients/carers
For doctors
MBBS BSc (Med) MPH FRACP PhD
Clinical interests
- Breast cancer
- Head and neck cancer
- Skin cancer
Languages
Fluent
- English
- Korean / 한국어
Biography
Special clinical interest in breast, skin (melanoma) and head and neck cancers.
A/Prof John Park completed his Medical Oncology training at Westmead, Nepean, Blacktown and Orange hospitals. He undertook a further fellowship in melanoma as a clinical trials fellow at Westmead Hospital affiliated with the Melanoma Institute Australia. A/Prof Park was awarded Fellowship of the Royal Australasian College of Physicians in 2017. He is appointed at Nepean Hospital as a Staff Specialist.
A/Prof Park is passionate about clinical trials and currently leads Phase I clinical trials at Macquarie University. He has extensive experience in Phase I–III clinical trials in adult solid tumours.
After completing a Master of Public Health at the University of Sydney, A/Prof Park was awarded his PhD at Macquarie University in 2023, titled “Oncogenic Signalling in Uveal Melanoma”. A/Prof Park is a Conjoint Associate Professor at Macquarie University and a Senior Clinical Lecturer at the University of Sydney.
In his spare time, he enjoys outdoor sports, travelling, and spending time with his family.
More information
John’s research interests include basic and translational research.
- American Society of Clinical Oncology (ASCO)
- European Society for Medical Oncology (ESMO)
- Medical Oncology Group of Australia (MOGA)
- Thoracic Oncology Group of Australasia (TOGA)
- Yao, H., Yan, M., Tong, Z., Wu, X., Ryu, M., Park, J., Kim, J., Zhong, Y., Zhao, Y., Voskoboynik, M., Yin, Y., Liu, K., Kaubisch, A., Liu, C., Zhang, J., Wang, S., Im, S., Ganju, V., Barve, M., Li, H., Ye, C., Roy, A., Bai, L., Yen, C., Gu, S., Lin, Y., Wu, L., Bao, L., Zhao, K., Shen, Y., Rong, S., Zhu, X., & Song, E. (2024). Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2–directed antibody–drug conjugate, in human epidermal growth factor receptor 2–expressing or mutated advanced solid tumors: A global phase I trial . Journal of Clinical Oncology, 42(29), 3453–3465.
- Smith-Uffen, M., Park, J., Parsonson, A., Kiely, B., & Vasista, A. (2024). Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy . The Oncologist, 29(11), 922–930.
- Park, J., Hamad, S., Stewart, A., Carlino, M., Lim, S., & Rizos, H. (2024). PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma . Oncogenesis, 13(1), 9.
- Park, J., Diefenbach, R., Joshua, A., Kefford, R., Carlino, M., & Rizos, H. (2018). Oncogenic signaling in uveal melanoma . Pigment Cell & Melanoma Research, 31(6), 661–672.
- Parakh, S., Park, J., Mendis, S., Rai, R., Xu, W., Lo, S., Kefford, R., Long, G., & Carlino, M. (2017). Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases . British Journal of Cancer, 116(12), 1558–1563.
- Sabanathan, D., Park, J., Marquez, M., Francisco, L., Byrne, N., & Gurney, H. (2017). Cure in advanced renal cell cancer: Is it an achievable goal? . The Oncologist, 22(12), 1470–1477.
- Park, J., Boddy, A., Liu, X., Harris, D., Lee, V., Kefford, R., & Carlino, M. (2017). Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis . Pigment Cell & Melanoma Research, 30(1), 68–71.
